WO2009061491A3 - Type iii secretion inhibitors and uses thereof - Google Patents

Type iii secretion inhibitors and uses thereof Download PDF

Info

Publication number
WO2009061491A3
WO2009061491A3 PCT/US2008/012610 US2008012610W WO2009061491A3 WO 2009061491 A3 WO2009061491 A3 WO 2009061491A3 US 2008012610 W US2008012610 W US 2008012610W WO 2009061491 A3 WO2009061491 A3 WO 2009061491A3
Authority
WO
WIPO (PCT)
Prior art keywords
type iii
iii secretion
secretion inhibitors
inhibitors
aspects
Prior art date
Application number
PCT/US2008/012610
Other languages
French (fr)
Other versions
WO2009061491A2 (en
Inventor
Jon Goguen
Ning Pan
Original Assignee
University Of Massachusetts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Massachusetts filed Critical University Of Massachusetts
Priority to US12/742,043 priority Critical patent/US8716283B2/en
Publication of WO2009061491A2 publication Critical patent/WO2009061491A2/en
Publication of WO2009061491A3 publication Critical patent/WO2009061491A3/en
Priority to US14/269,459 priority patent/US9340505B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

The invention, in some aspects, relates to compounds and compositions useful for inhibiting Type III secretion systems in pathogenic bacteria, such as Yersinia Pestis. In some aspects, the invention relates to methods for discovering inhibitors of the Type III secretion system and uses of such inhibitors in the treatment and prevention of disease.
PCT/US2008/012610 2007-11-07 2008-11-07 Type iii secretion inhibitors and uses thereof WO2009061491A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/742,043 US8716283B2 (en) 2007-11-07 2009-04-01 Type III secretion inhibitors, analogs and uses thereof
US14/269,459 US9340505B2 (en) 2007-11-07 2014-05-05 Type III secretion inhibitors, analogs and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US231607P 2007-11-07 2007-11-07
US61/002,316 2007-11-07

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/742,043 Continuation-In-Part US8716283B2 (en) 2007-11-07 2009-04-01 Type III secretion inhibitors, analogs and uses thereof
PCT/US2009/002022 Continuation-In-Part WO2009145829A1 (en) 2007-11-07 2009-04-01 Type iii secretion inhibitors, analogs and uses thereof

Publications (2)

Publication Number Publication Date
WO2009061491A2 WO2009061491A2 (en) 2009-05-14
WO2009061491A3 true WO2009061491A3 (en) 2009-12-17

Family

ID=40566426

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/012610 WO2009061491A2 (en) 2007-11-07 2008-11-07 Type iii secretion inhibitors and uses thereof

Country Status (1)

Country Link
WO (1) WO2009061491A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009145829A1 (en) 2008-04-01 2009-12-03 University Of Massachusetts Type iii secretion inhibitors, analogs and uses thereof
WO2011117259A1 (en) 2010-03-23 2011-09-29 Imba - Institut Für Molekulare Biotechnologie Gmbh Methods for identifying inhibitors of the type iii secretion system
WO2013148987A1 (en) * 2012-03-28 2013-10-03 The Regents Of The University Of Michigan Compositions and methods for treating intestinal bacterial infections

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058714A2 (en) * 1998-05-13 1999-11-18 Institut Pasteur Method for screening for inhibitors and activators of type iii secretion machinery in gram-negative bacteria
US20040106553A1 (en) * 2002-06-24 2004-06-03 Alekshun Michael N. Methods for preventing and treating microbial infections by modulating transcription factors
WO2006076009A2 (en) * 2004-04-23 2006-07-20 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058714A2 (en) * 1998-05-13 1999-11-18 Institut Pasteur Method for screening for inhibitors and activators of type iii secretion machinery in gram-negative bacteria
US20040106553A1 (en) * 2002-06-24 2004-06-03 Alekshun Michael N. Methods for preventing and treating microbial infections by modulating transcription factors
WO2006076009A2 (en) * 2004-04-23 2006-07-20 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ABE A ET AL: "Type-III effectors: Sophisticated bacterial virulence factors", COMPTES RENDUS - BIOLOGIES, ELSEVIER, PARIS, FR, vol. 328, no. 5, 1 May 2005 (2005-05-01), pages 413 - 428, XP004878377, ISSN: 1631-0691 *
ADAMS L G ET AL: "The chemotherapeutic efficacy of imidocarb dihydrochloride on concurrent bovine anaplasmosis and babesiosis. II. The effects of multiple treatments", TROPICAL ANIMAL HEALTH AND PRODUCTION, LIVINGSTONE, HARLOW, GB, vol. 6, no. 2, 1 May 1974 (1974-05-01), pages 79 - 84, XP009119423, ISSN: 0049-4747 *
BAILEY ET AL: "Small molecule inhibitors of type III secretion in Yersinia block the Chlamydia pneumoniae infection cycle", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 581, no. 4, 12 February 2007 (2007-02-12), pages 587 - 595, XP005884159, ISSN: 0014-5793 *
HUNG ET AL: "Chemotherapeutic efficacy of imidocarb dipropionate on experimental Eperythrozoon ovis infection in sheep", TROPICAL ANIMAL HEALTH AND PRODUCTION, LIVINGSTONE, HARLOW, GB, vol. 18, no. 2, 1 January 1986 (1986-01-01), pages 97 - 102, XP009119343, ISSN: 0049-4747 *
NORDFELTH R ET AL: "Small-molecule inhibitors specifically targeting type III secretion", INFECTION AND IMMUNITY, vol. 73, no. 5, May 2005 (2005-05-01), pages 3104 - 3114, XP002536122, ISSN: 0019-9567 *
WILEY ET AL: "Induction of the Yersinia Type 3 Secretion System as an All-or-None Phenomenon", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 373, no. 1, 14 September 2007 (2007-09-14), pages 27 - 37, XP022250528, ISSN: 0022-2836 *

Also Published As

Publication number Publication date
WO2009061491A2 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
AP2010005480A0 (en) Small molecule inhibitors for the treatment or prevention of denque virus infection.
WO2010090860A3 (en) Methods and compositions for treating bacterial infection
WO2008051416A3 (en) Compounds that inhibit the activity of hsp90 for treating infections
WO2011032169A3 (en) Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same
WO2008115281A3 (en) Compounds for treating viral infections
WO2009152356A3 (en) Compounds and compositions useful for the treatment of malaria
WO2009129267A3 (en) Small molecule inhibitors of the pleckstrin homology domain and methods for using same
WO2009156462A3 (en) Organic compounds
WO2009140309A3 (en) Boron-containing small molecules
WO2009043889A3 (en) Oxadiazole derivatives
MX2009006536A (en) Organic compounds and their uses.
EP3409666A3 (en) Seca inhibitors and methods of making and using thereof
WO2008067219A3 (en) Quinazolinone modulators of tgr5
WO2009117421A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
WO2010062377A3 (en) Methods and compositions for the detection and treatment of preeclampsia
WO2010079431A3 (en) Compounds for the prevention and treatment of cardiovascular disease
WO2008061724A3 (en) Compositions comprising carnosic acid 12-methylether
WO2010033977A3 (en) Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
WO2012170807A3 (en) Anti-pseudomonas psl binding molecules and uses thereof
WO2011017132A3 (en) Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
WO2009114461A3 (en) Angiotensin (1-7) dosage forms and uses thereof
WO2010053573A3 (en) Screen for inhibitors of filovirus and uses therefor
WO2009094560A3 (en) Thienopyranones as kinase inhibitors
WO2012017321A3 (en) Treatment for dyslipidemia
WO2011150457A3 (en) Haematopoietic-prostaglandin d2 synthase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08848351

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08848351

Country of ref document: EP

Kind code of ref document: A2